Pentoxifylline attenuates pulmonary inflammation and neutrophil activation in experimental acute pancreatitis

Pancreas. 2008 Jul;37(1):42-9. doi: 10.1097/MPA.0b013e3181612d19.

Abstract

Objectives: Acute pancreatitis (AP) is associated with a systemic inflammatory response. Pentoxifylline (PTX) has been shown to attenuate neutrophil activation and end-organ injury in shock states such as hemorrhage and sepsis. We hypothesized that PTX would down-regulate AP-induced lung injury.

Methods: Sprague-Dawley rats underwent catheterization of the pancreatic duct. Acute pancreatitis (n = 7) and AP/PTX animals (n = 7) received a retrograde infusion of 3.5% sodium taurocholate and intravenous treatment with normal saline or normal saline and PTX (25 mg/kg), respectively. Pulmonary neutrophil degranulation and sequestration were determined by zymography and detection of myeloperoxidase. Nuclear factor kappa B and mitogen-activated protein kinase phosphorylation was determined by Western blot. Cytokine-induced neutrophil chemoattractant was quantified by enzyme linked immunosorbent assay.

Results: Pulmonary histologic injury scores were attenuated in the AP/PTX group (P < 0.05). Plasma amylase levels remained unchanged. Pentoxifylline produced a significant decline in myeloperoxidase content and matrix metalloproteinase activity (P < 0.05). The increase in the phosphorylation of pulmonary nuclear factor kappa B, p38 mitogen-activated protein kinase, and extracellular-related signal kinase 1/2 observed after AP was not demonstrated with PTX (P < 0.05). Pentoxifylline supplementation reduced pulmonary cytokine-induced neutrophil chemoattractant levels by 50% (P < 0.05).

Conclusions: Pentoxifylline significantly attenuated histologic lung injury, pulmonary neutrophil activity, and proinflammatory signaling in a severe model of AP. Therefore, PTX may serve as an adjunct for the treatment of the inflammatory complications of severe AP.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Amylases / blood
  • Animals
  • Anti-Inflammatory Agents / pharmacology*
  • Chemokine CXCL1 / metabolism
  • Disease Models, Animal
  • Lung / drug effects*
  • Lung / enzymology
  • Lung / immunology
  • Lung / pathology
  • Male
  • Matrix Metalloproteinase 2 / metabolism
  • Matrix Metalloproteinase 9 / metabolism
  • NF-kappa B / metabolism
  • Neutrophil Activation / drug effects*
  • Pancreatitis / chemically induced
  • Pancreatitis / complications
  • Pancreatitis / drug therapy*
  • Pancreatitis / enzymology
  • Pancreatitis / immunology
  • Pentoxifylline / pharmacology*
  • Peroxidase / metabolism
  • Phosphodiesterase Inhibitors / pharmacology*
  • Phosphorylation
  • Pneumonia / enzymology
  • Pneumonia / etiology
  • Pneumonia / immunology
  • Pneumonia / pathology
  • Pneumonia / prevention & control*
  • Rats
  • Rats, Sprague-Dawley
  • Taurocholic Acid
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Anti-Inflammatory Agents
  • Chemokine CXCL1
  • Cxcl1 protein, rat
  • NF-kappa B
  • Phosphodiesterase Inhibitors
  • Taurocholic Acid
  • Peroxidase
  • p38 Mitogen-Activated Protein Kinases
  • Amylases
  • Matrix Metalloproteinase 2
  • Mmp2 protein, rat
  • Matrix Metalloproteinase 9
  • Pentoxifylline